Medical Predictive Science Corporation



Home	About MPSC	HeRO™	News	References	Links	Contact Us
HeRO™ Clinical Trial Achieves 1,650 Patient Enrollments September 25, 2008 - Charlottesville, VA: In a landmark trial evaluating the clinical outcomes of the HeRO™ heart rate characteristics monitor, Medical Predictive Science Corporation (MPSC) announced that 1,650 very low birth weight (VLBW) neonates have been enrolled to date. Sponsored by the National Institutes of Health, this trial will enroll a total of 3,000 premature infants upon its completion. In the world of treating neonatal infants, a 3,000 patient trial is exceptional. This large trial has been designed to demonstrate the improvement in patient outcomes for these premature infants whose physicians and nurses can view the HeRO™ Score. Specifically, the HeRO™ trial will evaluate the number of ventilator-free days, antibiotic usage, days in hospital, and mortality for infants who have their HeRO Scores shown versus hidden from the patient care team. Medical Predictive Science Corporation has developed the Heart Rate Observation System (HeRO™) for analyzing heart rate patterns. The HeRO™ System is a noninvasive monitor that is continuously available to the health care staff caring for the neonates and has been cleared for the purposes of identifying transient decelerations and reduced baseline variability. Advances in the medical practice have allowed physicians specializing in neonatal care to support the birth of premature infants as early as 21-22 weeks in the womb. Care for these very premature infants is complex and these infants have many risks and challenges that they must face in the early days and months of their lives. Medical research is continuously trying to improve the ability to care for premature infants with fewer complications in later life. "This clinical trial, of which MPSC is a supporter, will be pivotal to demonstrating the value of the HeRO™ System," said Will King, CEO of MPSC, "We are committed to utilizing the power of real-time computer analysis to improve patient care and outcomes. The HeRO™ system is now being used to monitor over 850 neonatal intensive care (NICU) beds in the USA." Where installed at the hospital, the HeRO system continuously monitors each of the NICU beds and provides scores to the physicians and nurses caring for the infant. Additional information about the clinical trial can be found at the NIH ClinicalTrials.gov website under the identifier NCT00307333. # # # Medical Predictive Science Corporation (http://www.mpsc.biz/) is engaged in the development of computational diagnostic and bio-informatic technologies for the healthcare industry. MPSC is committed to saving lives and reducing healthcare expenditures through the development of effective clinical diagnostic and decision support tools. These products use computational diagnostic methods to make the early diagnosis of clinical illness through continuous, non-invasive patient monitoring, and to provide diagnostic information as well as decision support to the physician. HeRO is a trademark of Medical Predictive Science Corporation.


About MPSC \| HeRO™ Product Information \| References Cite HeRO™ \| Contact Us \| Legal \| News \| Support \| Home © 2006. HeRO is a trademark of Medical Predictive Science Corporation.